Schroder Global Healthcare Z Acc
Latest (Mid) Price:
GBX 226.70
Day Change:
+0.40%
| Shares Class | Inc. |
|---|---|
| Yield | 0.18 |
| Total Expense Ratio | 0.00 |
Fund Performance
Cumulative Performance
Discrete Performance
MoneyAM Fund Centre
Quick Stats
| Fund Size | 452,203,000.00 | Launch Date | 22/05/2000 | Standard Initial Charge (%) | 0.00 |
|---|---|---|---|---|---|
| Currency | GBX | ISA Eligible | No | Annual Management Charge (%) | 0.75 |
| Sector | IMA UK Equity Income | Min Investment (£) | 1,000,000.00 | Total Expense Ratio (%) | 0.00 |
| ISIN | GB00B76V7Q08 | Min Topup (£) | 100,000.00 | Ongoing Charge (%) | 0.9300 (on 15/10/2019) |
Fund Objective
The fund aims to provide capital growth by investing in equities of healthcare and medical related companies worldwide. The fund is actively managed and invests at least 80% of its assets in equities of companies worldwide, which are engaged in healthcare provision, medical services and related products. The fund is positioned to benefit from the structural growth in demand for healthcare provision and medical treatments, supported by demographic trends, improving standards of living and technological advancements. The investment manager will position the fund to benefit from these strong themes by investing in areas such as biotechnology, generic drug manufacture and supply, pharmaceuticals, health insurance and hospital supplies. The fund may also invest directly or indirectly in other securities (including in other asset classes), countries, regions, industries or currencies, collective investment schemes (including Schroder funds), warrants and money market instruments, and hold cash. The fund may use derivatives with the aim of reducing risk and managing the fund more efficiently.
Fund Managers
John Bowler
John Joined Schroders in 2003.Investment career commenced in 1994.Currently Global Sector Specialist with responsibility for the healthcare sector and manager of the Schroder Medical Discovery Fund, as well as having primary research responsibility for Pan-European pharmaceuticals. Based in London John joined Schroders from AXA Investment Managers, where he had worked since 1998 in a global healthcare research role. He was voted top buy-side analyst for the pharmaceutical and healthcare sector in the Institutional Investor Pan European Equity survey in 2002.Before this, John worked at State Street Research & Management from 1997 as a fund manager / analyst.Earlier, John joined Hill Samuel Asset Management in 1994 as a graduate trainee, later becoming a junior fund manager for UK equities.Institute of Investment Management and Research (IIMR) qualified. Member of the CFA Society of the UK (CFA UK). PhD in Biochemistry & Physiology, from the University of Manchester. Degree in Biology from the University of Manchester.
Asset Breakdown
| Name | Weight |
|---|---|
| Australian Equities | 1.02% |
| Belgian Equities | 1.78% |
| Chinese Equities | 3.48% |
| Danish Equities | 0.48% |
| Dutch Equities | 2.00% |
| French Equities | 2.92% |
| German Equities | 5.96% |
| Italian Equities | 0.75% |
| Japanese Equities | 4.16% |
| Money Market | 3.63% |
| Swedish Equities | 2.02% |
| Swiss Equities | 9.89% |
| UK Equities | 0.82% |
| US Equities | 61.09% |
Region Breakdown
| Name | Weight |
|---|---|
| Australia | 1.02% |
| Belgium | 1.78% |
| China | 3.48% |
| Denmark | 0.48% |
| France | 2.92% |
| Germany | 5.96% |
| Italy | 0.75% |
| Japan | 4.16% |
| Money Market | 3.63% |
| Netherlands | 2.00% |
| Sweden | 2.02% |
| Switzerland | 9.89% |
| UK | 0.82% |
| USA | 61.09% |
Sector Breakdown
| Name | Weight |
|---|---|
| Financials | 0.42% |
| Health Care | 94.42% |
| Industrials | 1.30% |
| Money Market | 3.63% |
| Others | 0.23% |
Top 10 Holdings
| Name | Weight |
|---|---|
| UNITEDHEALTH GROUP INC | 6.15% |
| ABBOTT LABORATORIES | 4.10% |
| ROCHE HLDG AG | 3.88% |
| THERMO FISHER SCIENTIFIC INC | 3.75% |
| MERCK & CO INC(NEW) | 3.70% |
| BRISTOL MYERS SQUIBB SA | 3.57% |
| NOVARTIS AG | 3.53% |
| MEDTRONIC INC | 3.27% |
| LILLY (ELI) & CO | 3.09% |
| SANOFI | 2.92% |
Please remember that past performance is not a guide of future returns. The value of investments and the income from them can go down as well as up as a result of currency exchange and market fluctuations and investors may not get back the amount originally invested.
Fund data supplied by
